13 Obesity Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Obesity Studies in Tucson

NCT07654361Recruiting

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses ...

Tucson, AZPHASE33,600 participantsGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

View Study Details

NCT07743463Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance ...

Tucson, AZPHASE33,003 participantsAscletis Pharma (China) Co., Limited

View Study Details

NCT07794579Recruiting

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

This study will evaluate the efficacy and safety of orforglipron in participants with overweight and assess whether it helps reduce the future risk of obesity-related conditions, including type 2 diab...

Tucson, AZPHASE32,001 participantsEli Lilly and Company

View Study Details

NCT07351045Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multi...

Tucson, AZPHASE32,000 participantsHoffmann-La Roche

View Study Details

NCT07351058Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multi...

Tucson, AZPHASE31,600 participantsHoffmann-La Roche

View Study Details

NCT07743450Recruiting

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance ...

Tucson, AZPHASE31,560 participantsAscletis Pharma (China) Co., Limited

View Study Details

NCT07784270Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline a...

Tucson, AZPHASE31,500 participantsAstraZeneca

View Study Details

NCT06143956Recruiting

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight ma...

Tucson, AZPHASE21,481 participantsEli Lilly and Company

View Study Details

NCT07654374Recruiting

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T...

Tucson, AZPHASE31,100 participantsGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

View Study Details

NCT07282600Recruiting

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Pa...

Tucson, AZPHASE31,035 participantsEli Lilly and Company

View Study Details

NCT07392190Recruiting

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and ...

Tucson, AZPHASE3900 participantsEli Lilly and Company

View Study Details

NCT07589608Recruiting

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with ...

Tucson, AZPHASE2400 participantsEli Lilly and Company

View Study Details

NCT06672549Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesi...

Tucson, AZPHASE3125 participantsEli Lilly and Company

View Study Details

About Obesity Clinical Trials in Tucson

Obesity is a complex chronic disease involving an excessive amount of body fat that increases the risk of other diseases and health problems. It affects over 650 million adults worldwide. Treatment approaches include lifestyle modifications, medications (GLP-1 agonists), and bariatric surgery.

There are currently 13 obesity clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 20,305 participants. Research is being sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, Ascletis Pharma (China) Co., Limited, Eli Lilly and Company and 2 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Obesity Clinical Trials in Tucson — FAQ

Are there obesity clinical trials in Tucson?

Yes, there are 13 obesity clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What obesity treatments are being tested?

The 13 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for obesity.

Data updated October 12, 2026 from ClinicalTrials.gov